Quick Answer
Processa Pharmaceuticals, Inc. reported R&D Expense of $3.17 million for fiscal year 2020.
Processa Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2020 | $3.17M | +36.7% |
| 2019 | $2.32M | -24.8% |
| 2018 | $3.09M | +220.0% |
| 2017 | $964.2K | +14602.1% |
| 2016 | $6.6K | -77.6% |
| 2015 | $29.2K | -83.6% |
| 2014 | $178.1K | -33.3% |
| 2013 | $267.1K | -40.4% |
| 2012 | $448.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2022 | $2.04M | +38.5% | +38.5% |
| March 31, 2021 | $1.48M | +194.2% | +177.2% |
| September 30, 2020 | $532.6K | -9.0% | +24.7% |
| June 30, 2020 | $427.1K | -41.2% | -14.9% |
| March 31, 2020 | $501.8K | +3.5% | -14.2% |
| September 30, 2019 | $585.0K | -4.4% | -19.5% |
| June 30, 2019 | $726.9K | -32.5% | +50.0% |
| March 31, 2019 | $484.8K | -41.0% | -20.7% |
- Processa Pharmaceuticals, Inc. showed an increase of +36.7% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2020 period, Processa Pharmaceuticals, Inc.’s r&d expense has grown by 608.1% (from $448.0 thousand to $3.17 million).
- The most recent figure is from Processa Pharmaceuticals, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on March 25, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: